Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus Irinotecan in Metastatic Colorectal Cancer
NCT00493857Phase 2Terminated
- Sponsor
- YM BioSciences
- Start
- Jun 2007
- Primary completion
- Aug 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nimotuzumab in colorectal cancer (CRC) (2 cohorts), sponsored by YM BioSciences. Primary endpoint: Objective Response Rate. Started Jun 2007; status: terminated.
02
Drugs
nimotuzumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00493857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00493857.